Yi Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yi Li has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Yifei Zhong
Department of Nephrology, Longhua Hospital Shanghai University of Traditional Chinese Medicine
9 shared publications Fan Zhang
Department of Nephrology, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China
8 shared publicationsYan Bai
Department of Nephrology, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China
8 shared publicationsLiuyan Huang
Department of Nephrology, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China
6 shared publicationsAojiao Chu
Department of Nephrology, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China
2 shared publicationsHui Wang
Department of Anorectal Longhua Hospital Shanghai University of Traditional Chinese Medicine Shanghai China
2 shared publications
Latest Publications
- 7 April 2025
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 35 (9) , 104034
Association of intra-individual differences in estimated GFR by creatinine versus cystatin C with incident cardiovascular disease
- 7 April 2025
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 35 (9) , 104034
Association of intra-individual differences in estimated GFR by creatinine versus cystatin C with incident cardiovascular disease
- 18 March 2025
- Published by Elsevier in Clinical Nutrition ESPEN
- Vol. 67, 184-191
Association of sarcopenia index, a surrogate marker of muscle mass, and incident chronic kidney disease
- 18 March 2025
- Published by Elsevier in Clinical Nutrition ESPEN
- Vol. 67, 184-191
Association of sarcopenia index, a surrogate marker of muscle mass, and incident chronic kidney disease
- Open Access
- 24 February 2025
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 16 (1) , e13739
Gait Speed and All‐Cause Mortality in Whole‐Spectrum Chronic Kidney Disease: A Systematic Review and Meta‐Analysis Included 6217 Participants
Background: The quantitative relationship between gait speed and mortality risk in patients with chronic kidney disease remains unclear. This study aimed to conduct a meta‐analysis to estimate the risk of mortality associated with gait speed in chronic kidney disease (CKD) patients. Methods: Relevant studies published were identified through literature searches using Embase, PubMed and Web of Science. Prospective cohort studies of adult CKD patients that examined the relationship between gait speed and mortality were included. Random effects meta‐analyses based on restricted maximum likelihood to were used to calculate relative risk (RR) and 95% confidence interval (95% CI). The results of meta‐analyses were assessed using Grading of Recommendations, Assessment, Development and Evaluation framework. Results: Seventeen prospective cohort studies involving 6217 CKD patients (mean age range: 51.6–81.85 years; 44.3%–84% male) were included. Pooled analysis of 12 studies ( n = 4233) showed that lower gait speed was associated with a higher risk of all‐cause mortality compared to higher gait speed (RR = 2.138; 95% CI: 1.794–2.548; p < 0.001; I 2 = 16.0%; high‐certainty evidence) in CKD patients. Dose–response meta‐analysis of 6 studies ( n = 1650) revealed that each 0.1 m/s increase in gait speed was associated with a 25.7% lower risk of all‐cause mortality (RR = 0.743; 95% CI: 0.580–0.955; p = 0.018; I 2 = 45.0%; high‐certainty evidence). Conclusions: Slower gait speed is a strong predictor of all‐cause mortality in CKD patients, including those undergoing dialysis or kidney transplantation. Gait speed assessment should be incorporated into routine clinical evaluations to identify high‐risk patients and guide interventions aimed at improving physical function and survival outcomes. Trial Registration: PROSPERO registration number: CRD42022340135
- 24 February 2025
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 16 (1) , e13739
Open AccessGait Speed and All‐Cause Mortality in Whole‐Spectrum Chronic Kidney Disease: A Systematic Review and Meta‐Analysis Included 6217 Participants
Background: The quantitative relationship between gait speed and mortality risk in patients with chronic kidney disease remains unclear. This study aimed to conduct a meta‐analysis to estimate the risk of mortality associated with gait speed in chronic kidney disease (CKD) patients. Methods: Relevant studies published were identified through literature searches using Embase, PubMed and Web of Science. Prospective cohort studies of adult CKD patients that examined the relationship between gait speed and mortality were included. Random effects meta‐analyses based on restricted maximum likelihood to were used to calculate relative risk (RR) and 95% confidence interval (95% CI). The results of meta‐analyses were assessed using Grading of Recommendations, Assessment, Development and Evaluation framework. Results: Seventeen prospective cohort studies involving 6217 CKD patients (mean age range: 51.6–81.85 years; 44.3%–84% male) were included. Pooled analysis of 12 studies ( n = 4233) showed that lower gait speed was associated with a higher risk of all‐cause mortality compared to higher gait speed (RR = 2.138; 95% CI: 1.794–2.548; p < 0.001; I 2 = 16.0%; high‐certainty evidence) in CKD patients. Dose–response meta‐analysis of 6 studies ( n = 1650) revealed that each 0.1 m/s increase in gait speed was associated with a 25.7% lower risk of all‐cause mortality (RR = 0.743; 95% CI: 0.580–0.955; p = 0.018; I 2 = 45.0%; high‐certainty evidence). Conclusions: Slower gait speed is a strong predictor of all‐cause mortality in CKD patients, including those undergoing dialysis or kidney transplantation. Gait speed assessment should be incorporated into routine clinical evaluations to identify high‐risk patients and guide interventions aimed at improving physical function and survival outcomes. Trial Registration: PROSPERO registration number: CRD42022340135
- 19 October 2024
- Published by Elsevier in General Hospital Psychiatry
- Vol. 91, 122-129
Association of depressive symptoms and incident chronic kidney disease in middle-aged and older adults
- 19 October 2024
- Published by Elsevier in General Hospital Psychiatry
- Vol. 91, 122-129
Association of depressive symptoms and incident chronic kidney disease in middle-aged and older adults
- Open Access
- 24 September 2024
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 11, 1450561
Therapeutic effects of Kangxian Yanshen formula on patients with chronic kidney disease stages 3–4: a retrospective cohort study
Background: This study retrospectively evaluated the actual efficacy of Kangxian Yanshen Formula Chinese medicine on renal function-related indicators in chronic kidney disease (CKD) stage 3–4 patients.Methods: In this retrospective cohort study, we collected 212 adult CKD patients with baseline estimated glomerular filtration rate (eGFR) of 15–60 ml/min/1.73 m2. All participants received usual care (i.e., Western medications), and participants in the exposure group (n = 109) were additionally prescribed Kangxian Yanshen Formula Chinese medicine. The primary outcome was an adjusted hazard risk and 95% confidence interval (95% CI) of a 30% decrease in eGFR at month 36 from baseline.Results: In terms of eGFR, among participants treated with additional Kangxian Yanshen Formula, after adjusting for covariates, there was a 57.1% reduction in the risk of a 30% decline from baseline in eGFR among participants in the Kangxian Yanshen Formula group compared with the Western medicine group (adjusted hazard risk: 0.429; 95% CI 0.269–0.682). In addition, participants in the Kangxian Yanshen Formula group had a significantly higher change in eGFR from baseline to month 12 than those in the western medicine group (3.40 ± 11.62 versus −3.87 ± 8.39; between-group difference Δ5.61 [± 2.26 standard deviation] mL/min/1.73 m2; P = 0.014). Participants in both groups showed a decreasing trend in eGFR at months 24 and 36.Conclusion: In patients with stage 3–4 CKD, Kangxian Yanshen Formula Chinese medicine therapy may help delay eGFR decline, but high-quality randomized controlled trials are needed to validate the results further.
- 24 September 2024
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 11, 1450561
Open AccessTherapeutic effects of Kangxian Yanshen formula on patients with chronic kidney disease stages 3–4: a retrospective cohort study
Background: This study retrospectively evaluated the actual efficacy of Kangxian Yanshen Formula Chinese medicine on renal function-related indicators in chronic kidney disease (CKD) stage 3–4 patients.Methods: In this retrospective cohort study, we collected 212 adult CKD patients with baseline estimated glomerular filtration rate (eGFR) of 15–60 ml/min/1.73 m2. All participants received usual care (i.e., Western medications), and participants in the exposure group (n = 109) were additionally prescribed Kangxian Yanshen Formula Chinese medicine. The primary outcome was an adjusted hazard risk and 95% confidence interval (95% CI) of a 30% decrease in eGFR at month 36 from baseline.Results: In terms of eGFR, among participants treated with additional Kangxian Yanshen Formula, after adjusting for covariates, there was a 57.1% reduction in the risk of a 30% decline from baseline in eGFR among participants in the Kangxian Yanshen Formula group compared with the Western medicine group (adjusted hazard risk: 0.429; 95% CI 0.269–0.682). In addition, participants in the Kangxian Yanshen Formula group had a significantly higher change in eGFR from baseline to month 12 than those in the western medicine group (3.40 ± 11.62 versus −3.87 ± 8.39; between-group difference Δ5.61 [± 2.26 standard deviation] mL/min/1.73 m2; P = 0.014). Participants in both groups showed a decreasing trend in eGFR at months 24 and 36.Conclusion: In patients with stage 3–4 CKD, Kangxian Yanshen Formula Chinese medicine therapy may help delay eGFR decline, but high-quality randomized controlled trials are needed to validate the results further.
- 24 May 2024
- Published by Elsevier in Sleep Medicine
- Vol. 119, 526-534
Prevalence of obstructive sleep apnea in whole spectrum chronic kidney disease patients: A systematic review and meta-analysis
- 24 May 2024
- Published by Elsevier in Sleep Medicine
- Vol. 119, 526-534
Prevalence of obstructive sleep apnea in whole spectrum chronic kidney disease patients: A systematic review and meta-analysis
- Open Access
- 9 May 2024
- Published by Taylor & Francis in Renal Failure
- Vol. 46 (1) , 2349187
Exercise training and chronic kidney disease: characterization and bibliometrics of citation classics of clinical intervention trials
In recent years, CKD has become the ninth leading cause of death in high-income countries, and its incidence is increasing yearly, with a trend toward younger people [1]. The global loss of life ex...
- 9 May 2024
- Published by Taylor & Francis in Renal Failure
- Vol. 46 (1) , 2349187
Open AccessExercise training and chronic kidney disease: characterization and bibliometrics of citation classics of clinical intervention trials
In recent years, CKD has become the ninth leading cause of death in high-income countries, and its incidence is increasing yearly, with a trend toward younger people [1]. The global loss of life ex...
- Open Access
- 22 January 2024
- Published by Taylor & Francis in Renal Failure
- Vol. 46 (1) , 2305855
Thresholds of handgrip strength for all-cause mortality in patients with chronic kidney disease: a secondary systematic review with dose-response meta-analysis
Although handgrip strength is associated with all-cause mortality in patients with chronic kidney disease (CKD), whether this relationship is dose-related is unknown. Therefore, we examined dose-response relationships between handgrip strength and all-cause mortality in CKD patients based on previous studies by meta-analysis. Data sources included three electronic databases (PubMed, Web of Science, and Embase) from inception through October 2023. The included cohort was a CKD population not limited to disease stage, and their handgrip strength was objectively measured. Two researchers independently screened studies, extracted data, and assessed the risk of bias. We utilized estimates of handgrip strength categories using robust-error meta-regression (REMR), pooled study-specific estimates, and established dose-response relationships. Outcomes of interest included only all-cause mortality. A total of 18 studies with 4810 participants (aged 47-71 years) were included. REMR modeling showed a U-shaped trend of association between handgrip strength and all-cause mortality in patients with CKD. Higher handgrip strength values, from 10 kg to approximately 28 kg, were associated with lower mortality risk. After that, the risk of death increased slightly. A U-shaped association exists between handgrip strength and all-cause mortality risk in CKD patients. Future studies with quantitative measurements for each CKD stage will help to determine precise relative risk estimates between handgrip strength and mortality risk in patients with different stages of CKD.
- 22 January 2024
- Published by Taylor & Francis in Renal Failure
- Vol. 46 (1) , 2305855
Open AccessThresholds of handgrip strength for all-cause mortality in patients with chronic kidney disease: a secondary systematic review with dose-response meta-analysis
Although handgrip strength is associated with all-cause mortality in patients with chronic kidney disease (CKD), whether this relationship is dose-related is unknown. Therefore, we examined dose-response relationships between handgrip strength and all-cause mortality in CKD patients based on previous studies by meta-analysis. Data sources included three electronic databases (PubMed, Web of Science, and Embase) from inception through October 2023. The included cohort was a CKD population not limited to disease stage, and their handgrip strength was objectively measured. Two researchers independently screened studies, extracted data, and assessed the risk of bias. We utilized estimates of handgrip strength categories using robust-error meta-regression (REMR), pooled study-specific estimates, and established dose-response relationships. Outcomes of interest included only all-cause mortality. A total of 18 studies with 4810 participants (aged 47-71 years) were included. REMR modeling showed a U-shaped trend of association between handgrip strength and all-cause mortality in patients with CKD. Higher handgrip strength values, from 10 kg to approximately 28 kg, were associated with lower mortality risk. After that, the risk of death increased slightly. A U-shaped association exists between handgrip strength and all-cause mortality risk in CKD patients. Future studies with quantitative measurements for each CKD stage will help to determine precise relative risk estimates between handgrip strength and mortality risk in patients with different stages of CKD.
- Open Access
- 8 January 2024
- Published by Taylor & Francis in Renal Failure
- Vol. 46 (1) , 2301504
Therapeutic effects of acupuncture therapy for kidney function and common symptoms in patients with chronic kidney disease: a systematic review and meta-analysis
Purpose: The number of clinical reports of acupuncture therapy in chronic kidney disease (CKD) is gradually increasing. This systematic review and meta-analysis aim to examine the therapeutic role of acupuncture therapy in kidney function and common symptoms in CKD patients.Methods: We searched Embase, PubMed, Scopus, Web of Science, China National Knowledge Infrastructure, WanFang, and WeiPu for randomized controlled trials comparing acupuncture treatment with control or placebo groups. We assessed the effect of acupuncture therapy in CKD patients using a meta-analysis with the hartung-knapp-sidik-jonkman random effects model. In addition, we visualized keyword co-occurrence overlay visualization with the help of VOSviewer software to describe the research hotspots of acupuncture therapy and CKD.Results: A total of 24 studies involving 1494 participants were included. Compared to the control group, acupuncture therapy reduced serum creatinine levels (standardized mean difference [SMD]: -0.57; 95% CI -1.05 to -0.09) and relieved pruritus (SMD: -2.20; 95% CI -3.84, -0.57) in patients with CKD, while the TSA showed that the included sample size did not exceed the required information size. The included studies did not report acupuncture-related adverse events.Conclusions: Acupuncture is an effective and safe treatment for improving kidney function and relieving pruritic symptoms in patients with CKD, but the very low evidence may limit this conclusion. The TSA suggests that high-quality trials are needed to validate the efficacy of acupuncture therapy.
- 8 January 2024
- Published by Taylor & Francis in Renal Failure
- Vol. 46 (1) , 2301504
Open AccessTherapeutic effects of acupuncture therapy for kidney function and common symptoms in patients with chronic kidney disease: a systematic review and meta-analysis
Purpose: The number of clinical reports of acupuncture therapy in chronic kidney disease (CKD) is gradually increasing. This systematic review and meta-analysis aim to examine the therapeutic role of acupuncture therapy in kidney function and common symptoms in CKD patients.Methods: We searched Embase, PubMed, Scopus, Web of Science, China National Knowledge Infrastructure, WanFang, and WeiPu for randomized controlled trials comparing acupuncture treatment with control or placebo groups. We assessed the effect of acupuncture therapy in CKD patients using a meta-analysis with the hartung-knapp-sidik-jonkman random effects model. In addition, we visualized keyword co-occurrence overlay visualization with the help of VOSviewer software to describe the research hotspots of acupuncture therapy and CKD.Results: A total of 24 studies involving 1494 participants were included. Compared to the control group, acupuncture therapy reduced serum creatinine levels (standardized mean difference [SMD]: -0.57; 95% CI -1.05 to -0.09) and relieved pruritus (SMD: -2.20; 95% CI -3.84, -0.57) in patients with CKD, while the TSA showed that the included sample size did not exceed the required information size. The included studies did not report acupuncture-related adverse events.Conclusions: Acupuncture is an effective and safe treatment for improving kidney function and relieving pruritic symptoms in patients with CKD, but the very low evidence may limit this conclusion. The TSA suggests that high-quality trials are needed to validate the efficacy of acupuncture therapy.